ADMINISTRATIVE CORE: ABSTRACT Our inter-institutional U54 Serological Sciences Center of Excellence (“U54”) Administrative Core provides scientific and administrative oversight for all of the U54’s Projects and Cores. It also provides the main interface with patient advocates, NCI program staff, external and internal advisory boards, NCI SeroNet activities, other Lung Cancer NCI Networks, and collaborating institutions. The Center’s Administrative Core is led by three world leaders in lung cancer translational research, founders of the COVID-19 Lung Cancer Consortium (CLCC), who all have extensive experience leading large and complex lung cancer translational research programs: Dr. Fred R. Hirsch at the Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, Dr. John Minna at UTSW and Dr. Paul A. Bunn Jr. at the University of Colorado. The Administration Core PIs will work closely with the U54 overall Co-PI (Dr. Adolfo Garcia-Sastre), the U54’s Steering Committee, which consists of the overall PIs, the Administrative Core PIs, the Project and Core PIs, and a representative for our partner organization, the patient advocacy organization GO2 Foundation for Lung Cancer. The U54’s Steering Committee will have the assistance and advice of an Internal Advisory Board (IAB) and an External Advisory Board (EAB). The IAB will be established within the Mount Sinai Health System and will provide scientific advice and smooth access to required institutional resources. The EAB consists of international leaders in thoracic oncology and in medical virology and vaccinology and will assist with providing scientific advice and evaluating scientific progress with a special focus on lung cancer implications. The specific aims of the Administrative Core are: AIM 1: Direct the overall scientific integration and administrative management of the U54 and ensure effective communication between U54 Project and Core investigators; AIM 2: Oversee Administration of Patient Cohorts, Clinical Studies, Financial Reporting, and Regulatory Aspects; and AIM 3: Manage connection of the U54 with the NCI, SeroNet, and other lung cancer research (e.g. NCI Lung-SPORE) and patient advocacy networks. Thus, the Administrative Core will help this U54 to maximize its potential both internally (Mount Sinai, UTSW, and University of Colorado), and inter-institutionally, including interactions with the NCI Serological Sciences Network and the Frederick National Laboratory for Cancer Research (FNLCR). Successful completion of our U54 activities is expected to substantially increase our understanding of the association between lung cancer SARS-CoV-2 antibody response based on infection or vaccination, and ultimately be of significant service in designing lung cancer patient-specific SARS-CoV-2 preventive measures.